

Hong Kong Exchanges and Clearing Limited and The Stock of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited

和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that a subsidiary of the Company, Abbisko Therapeutics Co., Ltd., has completed the dosing of the first patient in the phase I clinical trial dose expansion part in US for ABSK021, an oral small molecule CSF-1R inhibitor.

This is a voluntary announcement made by the Company. The Group cannot guarantee that ABSK021 will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, November 17, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping, Dr. Chen Zhui and Mr. Yeh Richard as executive directors; Dr. Xia Gavin Guoyao and Ms. Tang Yanmin as non-executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics Completes Dosing of the First Subject in the Dose Expansion Part of Phase I Trial for CSF-1R Inhibitor ABSK021

17 November, 2021, Shanghai – Abbisko Therapeutics Co., Ltd. (“**Abbisko Therapeutics**” hereafter) today announced dosing of the first patient in the phase I clinical trial dose expansion part in US for ABSK021, an oral small molecule CSF-1R inhibitor. The purpose of dose expansion is to access the safety, tolerability, and preliminary anti-tumor activity of ABSK021 in patients with multiple solid tumors.

ABSK021 is a novel, orally available, highly selective, and highly potent small molecule inhibitor of CSF-1R. It has been previously shown by several clinical studies that blocking the CSF-1R signaling pathway could effectively modulate tumor microenvironment, relieve tumor immunosuppression, and synergize with other anti-cancer therapies such as immune checkpoint inhibitors to achieve tumor inhibition. Several clinical studies have also demonstrated that inhibition of CSF-1R activity could be used to treat tenosynovial giant cell tumor (TGCT), and to treat a variety of malignancies through combination with immuno-oncology and/or other therapeutic agents. As of the date of this article, no CSF-1R inhibitor has been approved in China.

ABSK021 is the first selective CSF-1R inhibitor independently developed by a Chinese company that has advanced into human clinical trial. A phase Ia dose escalation study has been completed in the US and demonstrated excellent PK/PD and safety profile of ABSK021 in human. In parallel, we have initiated ABSK021 phase I trial in China and have recruited several solid tumor patients including lung cancer patients.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), is an oncology focused biopharmaceutical company founded in Zhangjiang, Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and around the world. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built up an extensive pipeline of 14 innovative small molecule programs focused on precision oncology and immuno-oncology, including six clinical stage assets and eight pre-clinical stage assets. As of today, Abbisko Therapeutics has received ten IND or clinical trial approvals in four countries and regions.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.